US2007286851A1PendingUtilityA1

Method of Identifying Modulators of NOGO-Functions

41
Assignee: GLAXO GROUP LTDPriority: Jan 18, 2001Filed: Aug 10, 2007Published: Dec 13, 2007
Est. expiryJan 18, 2021(expired)· nominal 20-yr term from priority
Inventors:Walter BlackstockRichard HaleRabinder Kumar PrinjhaAdele Rowley
A61P 35/00A61P 25/00G01N 33/6896
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of treating acute neuronal injury by utilizing a BACE polypeptide that binds to Nogo, or compositions comprising such BACE polypeptide. Additional methods of treating a neoplastic, hyperproliferative or dysproliferative disorder, utilizing a BACE polypeptide that binds to Nogo, or compositions comprising such BACE polypeptide

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled)  
     
     
         16 . A method of treatment of acute neuronal injury, which method comprises administering an effective amount of a BACE polypeptide, to a human or animal in need of such treatment wherein said BACE polypeptide binds to Nogo.  
     
     
         17 . (canceled)  
     
     
         18 . A method according to  claim 16  wherein said acute neuronal injury is selected from spinal injury, stroke, brain injury and peripheral nervous system damage.  
     
     
         19 . (canceled)  
     
     
         20 . A composition comprising a BACE polypeptide, or a polynucleotide encoding a BACE polyeptide wherein said BACE polypeptide binds Nogo, and a pharmaceutically acceptable carrier or diluent.  
     
     
         21 . A method of treatment of a neoplastic, hyperproliferative or dysproliferative disorder, which method comprises administering an effective amount of a BACE polypeptide, a polynucleotide encoding a BACE to a human or animal in need of such treatment wherein said BACE polypeptide binds Nogo.  
     
     
         22 . (canceled)  
     
     
         23 . A method according to  claim 21  wherein said neoplastic, hyperproliferative or dysproliferative disorder is a disorder of the central nervous system.  
     
     
         24 . A method according to  claim 16  wherein said BACE polypeptide is selected from SEQ ID NO:2 and SEQ ID NO:13.  
     
     
         25 . A composition according to  claim 20  wherein said BACE polypeptide is selected from SEQ ID NO:2 and SEQ ID NO:13.  
     
     
         26 . A method according to  claim 21  wherein said BACE polypeptide is selected from SEQ ID NO:2 and SEQ ID NO:13.

Join the waitlist — get patent alerts

Track US2007286851A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.